Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs

Drug Development and Industrial Pharmacy

Volumn 43, Issue 2, 2017, Pages 338-346

  Forner, Kristin ^a   Roos, Carl ^b   Dahlgren, David ^b   Kesisoglou, Filippos ^c   Konerding, Moritz A ^d   Mazur, Johanna ^d   Lennernäs, Hans ^b   Langguth, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

antifoaming; aprepitant; cholesterol; fasted state simulated intestinal fluid; Intestinal segments; nanosized API; rat; sink conditions

Indexed keywords

ANTIFOAMING AGENT; APREPITANT; ATENOLOL; BOVINE SERUM ALBUMIN; BILE ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARENT PERMEABILITY; ARTICLE; CACO-2 CELL LINE; CONTROLLED STUDY; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DUODENUM; FOAMING; GASTROINTESTINAL ABSORPTION; ILEUM; IN VIVO STUDY; JEJUNUM; MALE; NONHUMAN; PARTICLE SIZE; RAT; TRANSEPITHELIAL POTENTIAL DIFFERENCE; ANIMAL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; HUMAN; INTESTINE; PHYSIOLOGY; SOLUBILITY;

ANIMALS; BILE ACIDS AND SALTS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HUMANS; INTESTINES; JEJUNUM; RATS; SOLUBILITY;

EID: 84994385620     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639045.2016.1251449     Document Type: Article

References (28)

1. Ginski M., Prediction of dissolution–absorption relationships from a dissolution/Caco-2 system. Int J Pharm 1999;177:117–25.
2. Kataoka M, Masaoka Y, Yamazaki Y, et al. In vitro system to evaluate oral absorption of poorly water-soluble drugs:simultaneous analysis on dissolution and permeation of drugs. Pharm Res 2003;20:1674–80.
3. Buch P, Langguth P, Kataoka M, Yamashita S., IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system. J Pharm Sci 2009;98:2001–9.
4. Bohets H, Annaert P, Mannens G, et al. Strategies for absorption screening in drug discovery and development. Curr Topics Med Chem 2001;1:367–83.
5. Galia E, Nicolaides E, Hörter D, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998;15:698–705.
6. Nicolaides E, Galia E, Efthymiopoulos C, et al. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 1999;16:1876–82.
7. Patel N, Forbes B, Eskola S, Murray J., Use of simulated intestinal fluids with Caco-2 cells and rat ileum. Drug Dev Ind Pharm 2006;32:151–61.
8. Wuyts B, Riethorst D, Brouwers J, et al. Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. Int J Pharm 2015;478:736–44.
9. Saha P, Kou JH., Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur J Pharm Biopharm 2002;54:319–24.
10. Khoshakhlagh P, Johnson R, Nawroth T, et al. Nanoparticle structure development in the gastro-intestinal model fluid FaSSIF mod6.5 from several phospholipids at various water content relevant for oral drug administration. Eur J Lipid Sci Technol 2014;116:1155–66.
11. Khoshakhlagh P, Johnson R, Langguth P, et al. Fasted-state simulated intestinal fluid “FaSSIF-C”, a cholesterol containing intestinal model medium for in vitro drug delivery development. J Pharm Sci 2015;104:2213–24.
12. Heinen C, Reuss S, Saaler-Reinhardt S, Langguth P., Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and carrageenans. Eur J Pharm Biopharm 2013;85:26–33.
13. Polentarutti BI, Peterson AL, Sjöberg AK, et al. Evaluation of viability of excised rat intestinal segments in the Ussing chamber:investigation of morphology, electrical parameters, and permeability characteristics. Pharm Res 1999;16:446–54.
14. Peternel L, Kristan K, Petruševska M, et al. Suitability of isolated rat jejunum model for demonstration of complete absorption in humans for bcs-based biowaiver request. J Pharm Sci 2012;101:1436–49.
15. Ungell A, Nylander S, Bergstrand S, et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998;87:360–6.
16. Nejdfors MEBJ P., Mucosal in vitro permeability in the intestinal tract of the pig, the rat, and man:species- and region-related differences. Scand J Gastroenterol 2009;35:501–7.
17. Zhou Y, Doyen R, Lichtenberger LM., The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. Biochim Biophys Acta 2009;1788:507–13.
18. Dial EJ, Rooijakkers SHM, Darling RL, et al. Role of phosphatidylcholine saturation in preventing bile salt toxicity to gastrointestinal epithelia and membranes. J Gastroenterol Hepatol 2008;23:430–6.
19. Hidalgo IJ., Assessing the absorption of new pharmaceuticals. Curr Topics Med Chem 2001;1:385–401.
20. Dahiya R, Brasitus TA., Distribution of glycosphingolipids and ceramide of rat small intestinal mucosa. Lipids 1986;21:112–16.
21. Katneni K, Charman SA, Porter CJH., An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity. J Pharm Pharmacol 2008;60:1311–19.
22. Yamashita S, Furubayashi T, Kataoka M, et al. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 2000;10:195–204.
23. Sawada GA, Ho NFH, Williams LR, et al. Transcellular permeability of chlorpromazine demonstrating the roles of protein-binding and membrane partitioning. Pharm Res 1994;11:665–73.
24. Deferme S, van Gelder J, Ingels F, et al. Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781. Int J Pharm 2002;234:113–19.
25. Vaghefi N, Guillochon D, Bureau F, et al. Effect of stabilising amino acids on the digestive absorption of heme and non-heme iron. Reprod Nutr Dev1998;38:559–66.
26. Kaplan MA., Loperamide-simethicone vs loperamide alone, simethicone alone, and placebo in the treatment of acute diarrhea with gas-related abdominal discomfort:a randomized controlled trial. Arch Family Med 1999;8:243–8.
27. Wu Y, Loper A, Landis E, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869:a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004;285:135–46.
28. Takano R, Furumoto K, Shiraki K, et al. Rate-limiting steps of oral absorption for poorly watersoluble drugs in dogs; prediction from a Miniscale Dissolution Test and a physiologically-based computer simulation. Pharm Res 2008;25:2334–44.